Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Everest Medicines Ltd. ( (HK:1952) ) just unveiled an announcement.
Everest Medicines has disclosed that non-executive director and honorary chairman Wei Fu, a substantial shareholder, has increased his stake in the company. Through a controlled entity, Fu bought 660,000 shares on the market on 14 May 2026 for about HK$20.7 million, paying an average of roughly HK$31.25 per share.
The purchase signals Fu’s strong confidence in Everest Medicines’ future prospects and long-term development, and he has indicated he may further increase his holdings subject to regulatory compliance. The move may be seen by investors as an endorsement of the company’s outlook, though the board has urged shareholders and potential investors to exercise caution when trading the stock.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$55.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Limited is a biopharmaceutical company listed in Hong Kong, focusing on the development and commercialization of innovative medicines. The company targets high unmet medical needs in its key markets and is backed by a board comprising executive, non-executive and independent non-executive directors with extensive industry and investment experience.
Average Trading Volume: 2,798,073
Technical Sentiment Signal: Sell
Current Market Cap: HK$11.36B
For an in-depth examination of 1952 stock, go to TipRanks’ Overview page.